Scarica l'app Stockscreener
7.52
2.59%
-0.20
Precedente Chiudi:
$7.72
Aprire:
$7.72
Volume 24 ore:
3.44M
Relative Volume:
1.89
Capitalizzazione di mercato:
$552.10M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.6103
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-2.84%
1M Prestazione:
+5.32%
6M Prestazione:
-13.56%
1 anno Prestazione:
-70.62%
Intervallo 1D:
$7.435
$7.8665
Intervallo di 1 settimana:
$7.37
$8.11
Portata 52W:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.52 | 566.78M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Acadian Asset Management LLC Makes New Investment in Arvinas, Inc. $ARVN - MarketBeat
Arvinas (NASDAQ:ARVN) Board of Directors Initiates Stock Repurchase Plan - MarketBeat
H.C. Wainwright reiterates Buy rating on Arvinas stock, maintains $18 target - Investing.com Canada
Portfolio Update: How do insiders feel about TNHLPJobs Report & Fast Momentum Stock Entry Tips - khodrobank.com
Arvinas (NASDAQ:ARVN) Earns Neutral Rating from Wedbush - MarketBeat
Arvinas reboots, cuts more staff; Porges joins Lazard - BioPharma Dive
Market Trends: Can CVR Energy Inc. navigate macro headwinds2025 Market WrapUp & Weekly Setup with ROI Potential - khodrobank.com
New Highs: Can Arvinas Inc outperform in the next rallyJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - khodrobank.com
BTIG Research Cuts Arvinas (NASDAQ:ARVN) Price Target to $10.00 - MarketBeat
Is WM Technology Inc. currently under institutional pressureJuly 2025 Rallies & Risk Controlled Stock Alerts - khodrobank.com
Stephens Lowers Arvinas (NASDAQ:ARVN) Price Target to $14.00 - MarketBeat
Arvinas (NASDAQ:ARVN) Raised to Strong-Buy at Barclays - MarketBeat
Arvinas stock price target lowered to $15 at Barclays on licensing plans - Investing.com
New Highs: What dividend growth rate does Arvinas Inc offer2025 Growth vs Value & Community Driven Trade Alerts - khodrobank.com
Returns Recap: Can Arvinas Inc reach all time highs this yearTake Profit & Step-by-Step Swing Trade Plans - khodrobank.com
Arvinas Holding Company: Strategic Shifts and Growth Opportunities Drive Buy Rating - TipRanks
Arvinas stock price target lowered to $14 at Stephens on Pfizer partnership update - Investing.com Canada
Amid investor pressures, Arvinas to cut 15% of staff as it reshapes drug strategy with Pfizer - Hartford Business Journal
BTIG Maintains Buy Rating on Arvinas (ARVN) Despite Lowered Pric - GuruFocus
Pfizer, Arvinas to sell rights to lead PROTAC one month after filing for FDA review - Endpoints News
Arvinas amends collaboration with Pfizer - The Pharma Letter
Arvinas stock rises as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com Canada
Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside - insights.citeline.com
ARVN: Stephens & Co. Lowers Price Target, Maintains Overweight R - GuruFocus
Arvinas stock rises as Cantor Fitzgerald reaffirms Overweight rating - Investing.com
Arvinas (NASDAQ:ARVN) Now Covered by Analysts at Barclays - MarketBeat
Arvinas stock price target lowered to $14 at Stephens on Pfizer partnership update By Investing.com - Investing.com Australia
Pharma News: Should I trade or invest in Arvinas IncJuly 2025 PostEarnings & High Win Rate Trade Tips - خودرو بانک
Wedbush Cuts Price Target on Arvinas to $9 From $10, Keeps Neutral Rating - MarketScreener
Arvinas and Pfizer to out-license breast cancer drug vepdegestrant By Investing.com - Investing.com Australia
Market Catalysts: Is Surf Air Mobility Inc impacted by rising ratesJuly 2025 Momentum & AI Forecasted Stock Moves - khodrobank.com
Arvinas (ARVN) Announces $100M Share Buyback Plan - GuruFocus
Arvinas announces $100M share repurchase program - MSN
Oppenheimer Maintains Arvinas(ARVN.US) With Hold Rating - 富途牛牛
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - The Mighty 790 KFGO
Arvinas (ARVN) and Pfizer Shift Commercialization Strategy for C - GuruFocus
Arvinas (ARVN) Refocuses Strategy and Optimizes Costs After Stra - GuruFocus
Pfizer (PFE) and Arvinas Seek Partner for Vepdegestrant's Commer - GuruFocus
Arvinas expects $4.5 million costs for workforce reductionSEC filing - MarketScreener
Arvinas provides update on collaboration with Pfizer - MarketScreener
Arvinas and Pfizer to out-license breast cancer drug vepdegestrant - Investing.com
Arvinas Announces 15% Workforce Reduction and Cost Savings - TipRanks
Arvinas, Pfizer to outlicense commercialization of cancer asset vepdegestrant - Seeking Alpha
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - GlobeNewswire
Arvinas, Inc. and Pfizer Jointly Agreed to Out-License the Commercialization Rights to Vepdegestrant to Third Party - MarketScreener
$100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback - Stock Titan
Update Recap: Can Arvinas Inc expand into new marketsJuly 2025 Macro Moves & Daily Stock Momentum Reports - خودرو بانک
ARVN: Barclays Initiates Coverage with Overweight Rating and $16 PT | ARVN Stock News - GuruFocus
Barclays initiates coverage on Arvinas stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Arvinas stock with Overweight rating - Investing.com
Market Review: Is Arvinas Inc forming a double bottom2025 Geopolitical Influence & Reliable Price Breakout Alerts - خودرو بانک
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):